Samsung Electronics Co. led the global smartphone industry in production with 78 million units in the third quarter, up 42 percent from the previous quarter and accounting for 23.2 percent of the total share.
The demand for Samsung's mobile devices increased in advanced markets during the pandemic.
According to market researcher TrendForce, the result reflects Samsung's focus on specific regional markets such as Europe and North America.
TrendForce added that due to economic stimulus policies and subsidies, smartphone sales in Samsung's markets have recovered.
Trailing Samsung were Chinese players Oppo and Xiaomi, which captured market shares of 13.4 percent and 13.2 percent.
Oppo manufactured 45 million smartphones in the third quarter, up 64 percent from the previous quarter, while Xiaomi produced 44.5 million smartphones, up 51 percent from the second quarter.


GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



